Raleigh Capital Management Inc. buys additional 78 shares of
Celanese Co., even as its stock performance falls behind competitors. Celanese declares
force majeure, due to supply disruptions that cause a pause in obligations.
Goldman Sachs Group Inc. reduce their shares in Celanese Co. despite rocky market conditions and lowered valuations.
Auxier Asset Management holds a significant stake in Celanese Co. worth $4.39 million.
Voisard Asset Management Group Inc. acquires 635 shares in Celanese Co. The stock performance shows high volatility,
underperforming on some days and
rising on other occasions. This irregularity persists in spite of the corporation being recognized as potentially undervalued and a top value stock for the long-term. Shareholders receive dividends, but are cautioned as the share price gap down following an analyst downgrade.
Bonding with chemical stocks, Celanese exhibits persistent growth in incremental revenue. Despite
first quarter earnings missing EPS estimates, its robust cash flow,
deleveraging in 2023 merit attention. The corporation's stake in
Polyplastics has been divested, allowing a new focus on its Acetyl Chain Business.
Partnerships with Glaukos for Glaucoma treatment and
Secarna for Antisense therapies signal expansion into bio-med projects.
Celanese Corporation CE News Analytics from Fri, 08 Dec 2023 08:00:00 GMT to Sun, 16 Jun 2024 14:27:53 GMT -
Rating -3
- Innovation 5
- Information 8
- Rumor -1
